|
| Press Releases |
|
 |
|
| Friday, August 26, 2016 |
|
|
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia. more info >> |
|
| Tuesday, August 23, 2016 |
|
|
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot |
| Eisai Co., Ltd. announced today that it will launch "Chocola BB Mouth Ulcer Repair Shot"(Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. more info >> |
|
| Monday, August 1, 2016 |
|
|
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session |
| Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). more info >> |
|
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
| Friday, July 22, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
| Wednesday, July 20, 2016 |
|
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
| Thursday, June 30, 2016 |
|
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, June 20, 2016 |
|
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
| AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
| Thursday, June 16, 2016 |
|
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
| Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
| Friday, June 3, 2016 |
|
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 1, 2025 00:42 HKT/SGT
|
|
|
AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing 
Mar 31, 2025 23:00 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 31, 2025 21:34 HKT/SGT
|
|
|
Huatai Securities Announces Dividend of RMB 3.7 per 10 Shares Following Record 2024 Performance
Mar 31, 2025 21:33 HKT/SGT
|
|
|
GF Securities Announces its 2024 Interim Results
Mar 31, 2025 21:33 HKT/SGT
|
|
|
Transforming Customer Experiences: Insights from Team Marksmen's CX Transformation Conclave
Mar 31, 2025 21:30 HKT/SGT
|
|
|
Vibe Marketing Tech Fest 2025 Will Focus on Convergence and Conversions
Mar 31, 2025 21:26 HKT/SGT
|
|
|
Local designer brands featured at 'Fashion Hong Kong Pop-up Salon' in Milan
Mar 31, 2025 21:20 HKT/SGT
|
|
|
Huatai Securities Reports Record 2024 Earnings and Advancement in Internationalization
Mar 31, 2025 21:18 HKT/SGT
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Mar 31, 2025 16:52 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Mar 31, 2025 16:30 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Mar 31, 2025 16:05 HKT/SGT
|
|
|
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
|
|
|
Yunkang's Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024
Mar 31, 2025 14:31 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Mar 31, 2025 11:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
